# Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

> **NCT00912743** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 33 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** olaparib

## Key facts

- **NCT ID:** NCT00912743
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2016-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912743, "Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00912743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*